Literature DB >> 24739128

Costs of treatment affect compliance to specific subcutaneous immunotherapy.

D Silva, A Pereira, N Santos, J L Plácido1.   

Abstract

BACKGROUND: Specific subcutaneous immunotherapy (SCIT) is cost-effective; however its economical burden can lead to non-adherence. We aimed to identify the reported reasons, patient's personal or socio-demographic characteristics and SCIT-related factors associated with non-adherence to SCIT.
METHODS: This is a cross-sectional, observational study held in a Portuguese University Hospital. All records from patients starting SCIT in the last 4 years were reviewed in July 2011. Those without registry of SCIT administration in the previous 3 months were included (n = 181). A telephonic survey was performed and 56 were confirmed as non-adherent; reasons for discontinuation were assessed. Univariate and multiple logistic regression models were developed using characteristics previously described as being associated with non-adhesion.
RESULTS: Economical burden of SCIT was the most important factor leading to treatment discontinuation (40%). In the univariate analysis, presence of family history of allergic disease treated with immunotherapy was associated with decreased OR of non-adherence to SCIT (OR [95%CI] = 0.31 [0.11- 0.88]). In the multiple logistic regression model, none of the factors was significantly associated with non-adherence.
CONCLUSION: Adherence is influenced by economic factors. More attention should be given to the impact of economic changes in allergic patient's treatment.

Entities:  

Keywords:  Allergen Immunotherapy; cost-effectiveness; economical factors; patient compliance; subcutaneous immunotherapy

Mesh:

Year:  2014        PMID: 24739128

Source DB:  PubMed          Journal:  Eur Ann Allergy Clin Immunol        ISSN: 1764-1489


  6 in total

Review 1.  Adherence to Sublingual Immunotherapy.

Authors:  Cristoforo Incorvaia; Marina Mauro; Gualtiero Leo; Erminia Ridolo
Journal:  Curr Allergy Asthma Rep       Date:  2016-02       Impact factor: 4.806

2.  Evaluation of safety and tolerability of a rush up-dosing allergen-specific immunotherapy with grass pollen, birch, hazel, and alder allergoid in children with allergic rhinoconjunctivitis, with or without asthma.

Authors:  Giovanni Traina; Alberto Martelli; Salvatore Barberi; Amelia Licari; Gian Luigi Marseglia; Maria Angela Tosca; Giorgio Ciprandi
Journal:  Acta Biomed       Date:  2021-02-04

3.  Prospective adherence to specific immunotherapy in Europe (PASTE) survey protocol.

Authors:  Melina Makatsori; Gianenrico Senna; Constantinos Pitsios; Ramon Lleonart; Ludger Klimek; Carlos Nunes; Maia Rukhadze; Barbara Rogala; Radoslaw Gawlik; Petr Panzner; Oliver Pfaar; Moises Calderon
Journal:  Clin Transl Allergy       Date:  2015-04-27       Impact factor: 5.871

4.  Severity and disease control before house dust mite immunotherapy initiation: ANTARES a French observational survey.

Authors:  Pascal Demoly; Anne Broué-Chabbert; François Wessel; Antoine Chartier
Journal:  Allergy Asthma Clin Immunol       Date:  2016-04-11       Impact factor: 3.406

5.  An accelerated dose escalation with a grass pollen allergoid is safe and well-tolerated: a randomized open label phase II trial.

Authors:  A M Chaker; B Al-Kadah; U Luther; U Neumann; M Wagenmann
Journal:  Clin Transl Allergy       Date:  2016-02-02       Impact factor: 5.871

6.  Adherence to Allergen Subcutaneous Immunotherapy is Increased by a Shortened Build-Up Phase: A Retrospective Study.

Authors:  Cristiano Caruso; Barbara Bramé; Diego Bagnasco; Alessia Cocconcelli; Valeria Ortolani; Valerio Pravettoni; Sergio Scarpa; Giuliana Zisa; Giovanni Passalacqua; Stefania Colantuono
Journal:  Biomed Res Int       Date:  2020-02-18       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.